Quantitative estimation of myocardial fibrosis based on receptor occupancy for β2-adrenergic receptor agonists in rats

Journal of Toxicological Sciences

Volumn 29, Issue 3, 2004, Pages 179-186

  Tanaka, Satoru ^a   Momose, Yasunori ^a   Tsutsui, Masaru ^a   Kishida, Tomoyuki ^a   Kuroda, Junji ^a   Shibata, Nobuo ^a   Yoshida, Takemi ^b   Yamagishi, Ryoichi ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Myocardial fibrosis; Receptor occupancy; 2 adrenergic receptor agonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; SALBUTAMOL SULFATE; TERBUTALINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BETA ADRENERGIC STIMULATION; CARDIOTOXICITY; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; HEART MUSCLE FIBROSIS; HEART RATE; MALE; NONHUMAN; PATHOPHYSIOLOGY; RAT; RECEPTOR OCCUPANCY; THEORY; TOXICOKINETICS;

ANIMALIA;

EID: 4644324247     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.29.179     Document Type: Article

References (17)

1. Bergés, R., Segura, J., Torre, X. and Ventura, R. (1999): Analytical methodology for enantiomers of salbutamol in human urine for application in doping control. J. Chromatogr., 723, 173-184.
2. Buckner, C.K. and Abel, P. (1974): Studies on the effects of the enantiomers of soterenol, trimetoquinol and salbutamol on beta adrenergic receptors of isolated guinea-pig atria and trachea. J. Pharm. Exp. Ther., 189, 616-625.
3. Hochhaus, G. and Möllmann, H. (1992): Pharmacokinetic/ pharmacodynamic characteristics of the β-2-agonists terbutaline, salbutamol and fenoterol. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 342-362.
4. Jack, D. (1991): The 1990 Lilly prize lecture; A way of looking at agonism and antagonism: Lessons from salbutamol, salmeterol and other β-adrenoceptor agonists. Br. J. Clin. Pharmacol., 31, 501-514.
5. Johnson, M. (1998): The β-Adrenoceptor. Am. J. Respir. Crit. Care. Med., 158, S146-S153.
6. Källström, B.L., Sjöberg, J. and Waldeck, B. (1996): Steric aspects of formoterol and terbutaline: Is there an adverse effect of the distomer on airway smooth muscle function? Chirality, 8, 567-573.
7. Libretto, S.E. (1994): A review of the toxicology of salbutamol (albuterol). Arch Toxicol., 68, 213-216.
8. Magnusson, G. and Hansson, E. (1973): Myocardial necrosis in the rat: A comparison between isoprenaline, orciprenaline, salbutamol and terbutaline. Cardiology, 58, 174-180.
9. Morgan, D.J., Paull, J.D., Richmond, B.H., Wilson, E.E. and Ziccone, S. P. (1986): Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br. J. Clin. Pharmacol., 22, 587-593.
10. Nyberg, L. (1984): Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur. J. Resp. Dis., 134 (Suppl.), 149-160.
11. Sawada, Y., Yamada, Y. and Iga, T. (1997): Quantitative Evaluation of pharmacological effects and adverse effects based on receptor occupancy theory. Yakugaku Zasshi., 117, 65-90.
12. Summers, R. J., Molenaar, P. and Stephenson, J. A. (1987): Autoradiographic localization of receptors in the cardiovascular system. TIPS., 8, 272-276.
13. Vago, T., Bevilacqua, M., Dagani, R., Meroni, R., Frigeni, G., Santoliß, C. and Norbiato, G. (1984): Comparison of rat and human left ventricle beta-adrenergic receptors: Subtype heterogeneity delineated by direct radioligand binding. Biochem. Biophys. Res. Commun., 121, 346-354.
14. Waldeck, B. (2002): β-Adrenoceptor agonists and asthma - 100 years of development. Eur. J. Pharmacol., 445, 1-12.
15. Yamada, Y., Shibuya, F., Hamada, J., Sawada, Y. and Iga, T. (1995a): Prediction of sleep disorders induced by β-adrenergic receptor blocking agents based on receptor occupancy. J. Pharmacokinet. Biopharm., 23, 131-145.
16. Yamada, Y., Matsuyama, K., Ito, K., Sawada, Y. and Iga, T. (1995b): Risk assessment of adverse pulmonary effects induced by adrenaline β-receptor antagonists and rational drug dosage regimen based on receptor occupancy. J. Pharmacokinet. Biopharm., 23, 463-478.
17. 2 receptor occupancy. Synapse, 46, 32-37.